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Abstract 
The TGF-β  pathway plays a central role in tissue homeostasis and morphogenesis.  
It transduces a variety of extracellular signals into intracellular transcriptional 
responses that control a plethora of cellular processes, including cell growth, 
apoptosis, and differentiation.  We use computational modeling to show that 
coupling of signaling with receptor trafficking results in a highly versatile signal-
processing unit, able to sense by itself absolute levels of ligand, temporal changes in 
ligand concentration, and ratios of multiple ligands. This coupling controls whether 
the response of the receptor module is transient or permanent and whether or not 
different signaling channels behave independently of each other. Our computational 
approach unifies seemingly disparate experimental observations and suggests 
specific changes in receptor trafficking patterns that can lead to phenotypes that 
favor tumor progression. 
 
Introduction 
The TGF-β signal transduction pathway follows an apparently straightforward 
downstream cascade, progressing sequentially from the interaction of ligands with 
transmembrane receptors, through phosphorylation of mediator Smad proteins, to 
transcriptional responses (Figure 1).  The simple logic of this signal transduction cascade 
strongly contrasts with the molecular complexity of the cellular processes involved and 
the wide diversity of responses triggered.  
 
At the molecular level, there is an intricate signal transduction machinery that integrates 
signals from the 42 known ligands of the TGF-β superfamily, funnels them through the 
two principal regulatory Smad (R-Smad) channels (Smad1/5/8 or Smad2/3) and 
subsequently leads to the wide-spread transcriptional control of over 300 target genes in a 
cell-context dependent manner (Kang et al., 2003b) (see Figure 2).  The components of 
this machinery include the members of the two main receptor families (type I and type II 
receptors), a myriad of adaptor proteins, and the trafficking apparatus of the cell, which 
shuttles proteins between different subcellular compartments. Each ligand induces the 
formation of a receptor complex with type I and type II receptors, which then signal 
through one of the two Smad channels (Goumans et al., 2003; Yamashita et al., 1994). 
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The ability of most ligands to bind several type I and type II receptors results in a 
complex ligand-receptor interaction network (Figure 2).   
 
At the phenotypic level, the responses are extremely diverse. The members of the TGF-β 
superfamily act prototypically as potent negative growth regulators but, depending on the 
cell type and context, they can also induce differentiation, apoptosis, cell migration, 
adhesion and extracellular matrix deposition.  TGF-β itself is of particular interest in 
cancer research. In epithelial cells, it suppresses cellular growth by inducing G1 arrest 
(mediated by transcriptional activation of p15 and p21) (Siegel and Massague, 2003) and 
its inactivation contributes to tumorigenesis. The versatility of the pathway in eliciting 
different types of behavior is perhaps best epitomized by the pervasive, rather 
paradoxical ability of TGF-β to change its function from suppressor to promoter of 
growth in epithelial cells during tumor progression (Cui et al., 1996; Siegel and 
Massague, 2003). 
 
Current theories for explaining the variety of responses to members of TGF-β 
superfamily of ligands focus mainly on the downstream transcriptional regulatory 
networks they activate: transcriptional co-factors of the R-Smads are expressed at 
different levels in a cell-specific manner, thereby modifying downstream responses. In 
fact, the role reversal of TGF-β from negative to positive growth regulator has been 
found to be associated with a phenotypic change known as epithelial-to-mesenchymal 
transition, in which cells change the co-factors recruited by the R-Smads and acquire 
motile phenotypes (Cui et al., 1996; Gotzmann et al., 2004; Thiery, 2003).  
 
It is striking, however, that such a variety of complex responses and intricate molecular 
components are connected through just two Smad channels by such a simple downstream 
signal transduction cascade. There is a richness of experimental observations that are 
difficult to reconcile with this observation. In particular, whether TGF-β acts as a growth 
suppressor or promoter can depend on whether the tumor cells were grown in vitro or in 
vivo (Steiner and Barrack, 1992). In these two different situations, the extracellular 
context determines the way in which cells respond to TGF-β. It has been suggested that 
TGF-β can suppress the growth of cells around the tumor, that it can shut down locally 
the immune system, and that it can promote angiogenesis. All these paracrine effects 
would help the growth of the tumor in vivo, where it has to compete with neighboring 
cells. So far, although appealing, none of these mechanisms has been identified as an 
alternative cause of the TGF-β role reversal.  
 
The most direct way in which the extracellular context can affect the functioning of the 
TGF-β pathway is through signaling of other ligands of the TGF-β superfamily. As we 
have mentioned, ligands and receptors form a complex interaction network, where 
multiple ligands share receptors, potentially coupling their signaling. All these 
interactions are in turn coupled to receptor trafficking, which is known to be a 
mechanism that regulates signal transduction (Gonzalez-Gaitan, 2003; Lauffenburger and 
Linderman, 1993). Trafficking has been investigated in detail in many signal transduction 
pathways, such as the epidermal growth factor receptor (EGFR) and G protein-coupled 
receptor (GPCR) pathways (Bohm et al., 1997; Tan et al., 2004; Wiley et al., 2003). The 
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typical way in which trafficking and signaling are coupled is by the induction of receptor 
internalization upon ligand binding and receptor activation, as for instance in the EGFR 
and GPCR pathways. After internalization, receptors can activate other signaling 
pathways, be modified in specific ways, and be targeted for degradation or recycling back 
to the plasma membrane. 
 
A peculiarity of the TGF-β pathway is that receptors are constitutively internalized, even 
in the absence of ligand (Di Guglielmo et al., 2003; Mitchell et al., 2004). The trafficking 
route that the receptors follow, however, depends on whether or not they are in a 
signaling complex (Figure 3). Different routes will trigger different signaling outcomes 
and affect how receptors are degraded. Therefore, although the explicit implementation 
of the coupling is different than in the EGFR and GPCR pathways, receptor trafficking 
and signaling are also tightly coupled in the TGF-β pathway. 
 
Taking all the current experimental data together, it is clear that many details of the 
underlying processes remain largely unknown. Recent experiments (Di Guglielmo et al., 
2003; Mitchell et al., 2004), however, provide key information that allows computational 
modeling to bridge the gap between potential molecular mechanisms and experimentally 
observable behavior. The TGF-β pathway is at a discovery stage where modeling can 
help to gain "functional" intuition.  
 
Here we characterize computationally the diverse potential types of behavior that the 
pathway structure itself can confer on the system. The types of behavior include 
responses to persistent changes in ligand concentration that can be transient or sustained 
and simultaneous responses to multiple ligands that can be passed downstream 
independently of or dependently on each other. 
 
A sustained response implies that the steady-state signaling activity is a function of the 
ligand concentration. In this case, the higher the ligand concentration, the higher the 
activity of the pathway. For a transient response that precisely returns to the prestimulus 
level, in contrast, the steady-state activity is always the same and the pathway can only 
detect changes in ligand concentration. When multiple ligands signal in a dependent 
fashion, the extent of the coupling can be such that one ligand can suppress the effects of 
another one. In this regime, the pathway does not detect ligand concentrations but ratios 
of concentrations.  
 
As we show here, all these types of behavior can be present in the TGF-β pathway. 
Which specific one is selected is determined by the interplay between trafficking and 
signaling. Thus the pathway can be set to detect, already at the receptor level, absolute 
levels of ligand, temporal changes in ligand concentration, and ratios of multiple ligands. 
Such a flexibility in the pathway behavior can lead to diverse physiological outcomes that 
have been associated with facilitated tumor progression. 
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A concise computational model 
In order to study the signal processing potential of the ligand-receptor network coupled 
with receptor trafficking, we assemble all the essential elements into a concise 
mathematical model that captures the logic of the underlying processes. The main goal is 
to represent as much complexity as possible by a small number of quantities that have 
direct experimental interpretation.  
 
The essential elements we consider are (Figure 4):  
i) Ligands induce the formation of receptor complexes with type II and type I 
receptors.  
ii) Receptors and ligand-receptor complexes can be present in two spatially 
distinct compartments: plasma membrane and internalized endosomes.  
iii) The signaling activity is proportional to the number of ligand-receptor 
complexes that are present in the internalized endosomes.  
iv) Receptors and ligand-receptor complexes are continuously internalized into 
endosomes and recycled back to the plasma membrane (Di Guglielmo et al., 
2003; Mitchell et al., 2004).  
v) Receptor degradation has a constitutive contribution, which is the same for 
free receptors and ligand-receptor complexes (Di Guglielmo et al., 2003; 
Mitchell et al., 2004). 
vi) Receptor degradation has a ligand-induced contribution, which affects only 
receptors that have been complexed with ligands (Di Guglielmo et al., 2003; 
Mitchell et al., 2004). 
 
We use these elements to develop a mathematical model based on rate equations that 
describe the dynamics of both how different molecular species transform into each other 
and how they traffic between the different cellular compartments. We assume that 
internalization, recycling, and degradation rates are proportional to the number of 
receptors or ligand-receptor complexes; and that the formation of ligand-receptor 
complexes is proportional to the ligand concentration and to the type I and type II 
receptor concentrations.  
 
In a first step towards characterizing the effects of the coupling of signaling with receptor 
trafficking, we consider that only a single type of ligand is present. Explicitly, we study 
how the components of the canonical TGF-β pathway —one ligand (TGF-β) and two 
receptors (Alk5 and TGFβRII), as emphasized in Figure 2— respond to changes in ligand 
concentration. The mathematical equations are shown in Figure 4. For typical trafficking 
rates (see Appendix I), this model closely reproduces the typical time courses of Smad 
phosphorylation upon addition of ligand (Figures 5a and 5b).  
 
The computational model can be used also to analyze how different parameters affect the 
behavior of the system. For instance, the time during which the signaling activity rises is 
related to the time required for internalization and recycling of the receptors. Thus, the 
signal will peak, or stop rising, at about 30-60 min after ligand addition. If the 
internalization and recycling rates are changed, the position of the peak changes 
accordingly (Figures 5c and 5d).   
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Other transmembrane receptor pathways, such as the EGFR pathway, have much faster 
kinetics; the EGFR pathway reaches peak activity as fast as 5 min after stimulation 
(Yarden and Sliwkowski, 2001). The main reason for these differences is that most of the 
EGF receptors are present in the plasma membrane and they are ready to signal upon the 
addition of ligand. A similar kinetics is also observed for many GPCRs. In the TGF-β 
pathway internalization occurs continuously and only about 5-10% of the receptors are 
present in the plasma membrane at a given time (Di Guglielmo et al., 2003). The 
remaining 90-95% of the receptors are internalized in endosomes. Receptors need to be 
recycled from the endosomes back to the plasma membrane in order to be able to interact 
with the ligand; and this process takes about 30 min on average.  
 
We can use the computational model to study the effects of different mechanisms, such 
as different forms of receptor degradation, on the behavior of the system.  It has been 
observed that the addition of ligand can stimulate the degradation of the receptors in two 
different ways. On the one hand, receptors complexed with ligand in the plasma 
membrane can be internalized through a lipid raft–caveolar degradation pathway without 
becoming active signalers (Di Guglielmo et al., 2003). The behavior obtained in this case 
is the one we have already described (Figure 5a). On the other hand, ligand-receptor 
complexes can follow the standard internalization clathrin pathway, signal, and then be 
targeted for degradation upon returning to the plasma membrane (Mitchell et al., 2004). 
Interestingly, when this mechanism is explicitly modeled, the behavior obtained (Figure 
5e) is qualitatively the same as the previous one (Figure 5a). Likewise, when both 
degradation mechanisms are considered together, a similar type of behavior is also 
obtained (Figure 5f). Thus, at this level of detail and for this range of parameter values, 
different mechanisms that implement ligand-induced degradation can lead to similar 
behavior.  
 
Control of the signal: transient vs. permanent responses 
How is it possible to modify the form in which the system responds to changes in TGF-β 
concentration? A mathematical analysis of the model (see below and Theory Box for 
details) indicates that the key quantity that determines the qualitative behavior of the 
pathway is the ratio of the constitutive to the ligand-induced rate of degradation, referred 
to, in short, as the constitutive-to-induced degradation ratio (CIR). This quantity 
compares the rates of two degradation processes and, in general, does not have a simple 
expression in terms of rate constants.  
 
Depending on the CIR, a permanent change in ligand concentration (as those in the insets 
of Figures 6a and 6b ) can elicit responses between two extremes: 
i) For low CIR, the ligand-induced degradation process dominates and there is a 
transient increase in signaling activity that returns to pre-stimulus levels 
(Figures 6a and 6b ). 
ii) For high CIR, the constitutive degradation process dominates and there is a 
permanently elevated level of signaling activity (Figures 6e and 6f). 
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For intermediate CIR, the behavior of the system is a mixture of both limiting types of 
behavior, with transient and permanent components (Figures 6c and 6d).  The precise 
parameter values influence the amplitude and characteristic time of the response (see for 
instance Figures 5c and 5d), but its qualitative shape, that is, whether the response is 
transient (Figures 6a and 6b) or permanent (Figures 6e and 6f), depends only on the CIR. 
 
The intuitive explanation of such types of behavior is as follows (for a detailed 
mathematical analysis see Appendix II). The probability for a receptor to bind the ligand, 
and therefore to become active, increases with the ligand concentration. If the ligand does 
not induce the degradation of receptors, the number of receptors remains constant and the 
total activity increases when the ligand concentration increases. If the ligand induces the 
degradation of the receptors, the number of receptors starts to decrease after ligand 
addition, which will eventually attenuate the signal. At steady state, the production and 
degradation of receptors equal each other. In the limit of the CIR going to zero, the signal 
adapts completely because degradation is proportional to the activation of receptors, and 
therefore activation is also proportional to the production of receptors. Thus, it is the 
receptor production rate, not the ligand concentration, that determines the steady-state 
signaling activity.  
 
There are clear examples in other signal transduction pathways that show that these two 
limiting types of behavior can potentially lead to different physiological outcomes. For 
instance, transient activation of the MAPK cascade by EGF leads to cell proliferation. In 
contrast, permanent activation of the MAPK cascade by NGF leads to cell differentiation. 
In both cases, activation of the MAPK cascade induces the expression of a negative 
regulator that shuts down the activity of this cascade. The differences between EGF and 
NGF have been attributed to additional pathways activated by NGF that can prevent the 
inactivation of the MAPK cascade (Vaudry et al., 2002). Our model shows that such 
transient and permanent types of behavior can also be achieved by just changing the 
trafficking patterns, in particular by adjusting the CIR, without the need of explicitly 
expressing a negative regulator to shut down the cascade after signaling. 
 
Remarkably, the duration of the signaling activity also seems to affect the physiological 
outcomes triggered by TGF-β (Nicolas and Hill, 2003). Epithelial cells that are sensitive 
to the antiproliferative effects of TGF-β (HaCaT and Colo-357) have sustained activity of 
more than 6 hours. In contrast, pancreatic tumor cell lines (PT45 and Panc-1) show short 
transient activity of about 1-2 hours. Such a short transient confers resistance to the 
antiproliferative effects of TGF-β but maintains other responses to TGF-β that can lead 
to increased malignancy and invasiveness (Nicolas and Hill, 2003). In our model, those 
differentiated types of behavior arise naturally for different trafficking patters. In 
particular, short transients and sustained responses imply a low and a high CIR, 
respectively.  
Control of the signals: coupled vs. uncoupled channels 
In vivo conditions, in contrast to those typical of in vitro experiments, expose cells to 
complex environments with many different growth factors. When multiple ligands of the 
TGF-β superfamily are present at the same time, they are likely to affect each other's 
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signaling (Figure 2).  To study how multiple simultaneous input signals are integrated 
into coordinated transcriptional responses, we extend our computational model to 
consider two ligands that signal through two different type II receptors and a shared 
common type I receptor (see Appendix III for the mathematical equations). This is the 
simplest case of signal integration.  
 
Intuitively, one should expect signals to be coupled when the shared receptor is saturated 
with ligands and uncoupled when ligand concentrations are low.  At saturation, 
increasing the concentration of one ligand, and thus the concentration of the 
corresponding ligand-receptor complex, will take the shared receptor away from the 
complex formed by the other ligand, thus decreasing its signaling.  
 
A mathematical analysis of the model (see Theory Box) indicates that even when the 
receptors are far from ligand-saturating conditions it is possible for signals to affect each 
other. The key element is again receptor trafficking. In essence, the coupling arises 
because the induction of degradation of the common receptor by one ligand attenuates the 
effects of the other ligand, which also requires the common receptor to transduce the 
signal. 
 
For pathways working away from receptor saturation, the interplay between trafficking 
and signaling determines how multiple simultaneous signals are passed downstream. As 
in the single ligand case, there are two extreme types of behavior:  
(i) For low CIR, the ligand-induced degradation process dominates and signals 
are completely coupled (Figures 7a and 7b). 
(ii) For high CIR, the constitutive degradation process dominates and signaling is 
uncoupled (Figure 7e and 7f). 
 
When the signals are completely coupled, the steady-state number of all ligand-receptor 
complexes remains constant and is independent of the ligand concentration. In this case, 
increasing one signal will decrease the other one by the same amount. When signals are 
uncoupled, the numbers of each species of ligand-receptor complexes change 
independently of each other. In general, for intermediate CIR, signals will show some 
degree of coupling (Figures 7c and 7d). These results demonstrate that changes in 
trafficking patterns, and the corresponding degradation, can alter the way in which the 
pathway integrates multiple, simultaneous signals. 
 
The completely coupled case is especially interesting because it indicates that one ligand 
can potentially inhibit the effects of another one.  Ligand-induced degradation is thus not 
only a mechanism for achieving transient responses, but also for coupling multiple 
signals.  The fact that TGF-β can signal not only via Alk5 but also via Alk1 and  Alk2 
(Figure 2) potentially couples TGF-β signals to those of Activin A, BMP 6, BMP 7, and 
MIS. Thus, if TGF-β loses its growth suppressor properties, it could promote growth by 
inhibiting other growth suppressor pathways. For instance, there are dominant negative 
TGFβRII mutants that when overexpressed attenuate the response to TGF-β (Dumont 
and Arteaga, 2003). The presence of any of these mutant receptors and TGF-β results in 
the formation of futile receptor complexes that can target receptors for degradation, or 
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take receptors away, that otherwise would be available to transduce the signals of other 
members of the TGF-β superfamily. 
 
Context-dependent response to TGF-β 
The role reversal of TGF-β from negative to positive growth regulator is a widespread 
feature of tumor progression and is often associated with endogenous overexpression of 
TGF-β. As we have mentioned in the introduction,  it is associated in some situations 
with the epithelial-to-mesenchymal transition (Gotzmann et al., 2004; Thiery, 2003). 
Under these conditions, the transcriptional program of tumor cells changes so that the 
Smad-activated genes promote rather than repress growth.  
 
In other situations such a transition does not seem to be present. It has been observed in 
breast, prostate, and colon cancer cell lines that the action of TGF-β as growth promoter 
or suppressor depends on whether the cells were grown in an in vitro environment or in 
vivo in mouse xenografts (Steiner and Barrack, 1992; Tobin et al., 2002; Ye et al., 1999). 
The reasons for such a change remain largely unknown. It has been speculated that it 
could be a consequence of the effects of TGF-β on the in vivo microenvironment of the 
tumor cells. Another possibility is that other grow factors, such as EGF, affect how TGF-
β is ultimately coupled to the cell cycle.   Our model explicitly shows that the role 
reversal is a potentially intrinsic consequence of the design of the ligand-receptor 
interaction network and trafficking machineries and that can be the result of TGF-β 
attenuating the effects of growth-suppressing signals of other members of the TGF-β 
superfamily that might be present in the in vivo cell environment. 
Simultaneous perfect adaptation and coupled signaling 
Our model also indicates that the conditions that give rise to completely coupled 
integration of multiple signals are the same that, in a single-ligand system, cause the 
signaling activity to completely adapt to its prestimulus level.  Remarkably, this concurs 
with observations in prostate cancer cell lines, which show that the in vivo context can 
not only make TGF-β a growth promoter but also that the in vitro response to TGF-β is 
transient (Steiner and Barrack, 1992).  One should expect the extracellular environment 
of growth factors to be more complex in vivo than in vitro.  This relationship between in 
vivo and in vitro behavior and its connection to the coupling between receptor trafficking 
and signaling underscores the importance of understanding how signal transduction 
pathways are embedded within the cellular microenvironment under physiologically 
relevant conditions.  Not only mutations in the canonical pathway but also changes in 
trafficking patterns can move the pathway to a different functioning point.  
 
The qualitative results of our model, such as the regimes leading to transient and 
permanent responses as well as to completely coupled and uncoupled modes of signal 
integration, do not depend on the details of the model but on general properties (see 
Theory Box). Thus the main ideas are also relevant to other signal transduction pathways 
that are coupled to receptor trafficking. In particular, revisiting the experimental data, one 
can see that the interplay between adaptation and signal integration (Theory Box) is also 
present in the EGFR pathway (see figure 4 and 5 of reference (Worthylake et al., 1999)), 
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in which down-regulation of erbB-2 by EGF concurs with adaptation of the signal 
transmitted by EGFR. 
Discussion 
Cellular functions are controlled by networks of interacting molecules that operate at 
different levels of organization (Hartwell et al., 1999; Stelling et al., 2004; Vilar et al., 
2003). Here, we have developed a concise computational model of the TGF-β pathway 
that shows that the receptors for the TGF-β superfamily of ligands are not just passive 
signal transducers. They are organized in a network that is able to process the signals 
before passing them downstream. Changes in receptor trafficking patterns can modify the 
type of behavior of the pathway in response to single and multiple ligand inputs. Already 
at the receptor level, the pathway can detect absolute levels of ligands, temporal changes 
in ligand concentration, and ratios of multiple ligands. This extra level of regulation can 
explain a wide variety of phenomena, such as the counterintuitive role reversal of TGF-β 
from suppressor to promoter of growth, and leads to a unified interpretation of seemingly 
disparate experimental observations. A key quantity that determines the qualitative 
behavior of the pathway is the constitutive-to-induced degradation ratio (CIR) of the 
receptors.  For low CIR, the pathway responds transiently to sustained changes in ligand 
concentration and the signaling activities of multiple simultaneous ligands become 
dependent on each other.  Ligand-induced degradation is thus not only a mechanism for 
achieving transient responses and perfect adaptation, but also for coupling multiple 
signals.  
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Theory Box: Coupled signaling and perfect adaptation  
Computational modeling offers precise insights into the functioning of the TGF-β 
pathway.  It is possible to go a step further and generalize the conditions that give rise to 
different qualitative types of behavior. 
 
Let us consider two ligands (l1 and l2), one type I receptor (RI) and two type II receptors 
(RII,1 and RII,2).  The type I receptor is shared among the two ligand-receptor complexes 
[l1 RI RII,1] and [l2 RI RII,2]. The following conservation equations refer to the common 
type I receptor at steady-state. 
 
Under stationary conditions, the number of receptors produced (by gene expression) is 
equal to the number of receptors degraded: 
 
p = dconst + dlid , 
 
where p is the receptor production rate; and dconst  and dlid are the constitutive and ligand-
induced degradation rates, respectively.  Assuming that a fraction δ of the activated 
receptors is degraded through a ligand-induced degradation process, we can express dlid 
as 
 
dlid = δ(ia1 + ia2) with δ ∈ (0, 1) , 
 
where ia1 and ia2 are the rates of formation of the ligand-receptor complexes ([l1 RI RII,1] 
and [l2 RI RII,2], respectively).  Therefore, 
 
p = dconst + δ(ia1 + ia2) . 
 
We now explicitly consider the following two limiting cases: 
Case 1: no ligand-induced degradation (dconst > 0, δ = 0) 
In this case, dlid = 0, which leads to p = dconst.  Since dconst ≡ dconst(RT) is a function of the 
total number of receptors RT, the previous condition indicates that the number of 
receptors remains constant RT = dconst
-1
(p), where dconst
-1
 is the inverse function of dconst.  
For instance, if the constitutive receptor degradation follows first order kinetics, dconst = 
γRT, then RT  = p/γ.  Under these conditions, if the rate of formation of complexes (ia1 + 
ia2) is small (for instance, for low ligand concentrations) compared with constitutive 
internalization and degradation, there is no coupling between signaling channels.  
Case 2: only ligand-induced degradation (dconst = 0, δ > 0) 
In this case dconst = 0 and p = δ(ia1 + ia2).  This implies that the formation of one ligand-
receptor complex excludes the formation of the other one. In this case, the number of 
receptors in the plasma membrane does not remain constant, but is adjusted so that for a 
given ligand concentration the rate of formation of complexes (ia1 + ia2) remains equal to 
p/δ.  As an explicit example, the kinetics ia1 = l1 RI RII,1 and ia2 = l1 RI RII,2 implies RI = 
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p/(l1 RII,1 + l2 RII,2).  Under these conditions, the completely coupled mode of signal 
integration arises even for low ligand concentrations. 
 
Connection with the temporal behavior  
The fact that the rate of formation of complexes remains constant implies that for the 
single ligand case (for example, ia2 = 0) we have p = δia1 when there is only ligand-
induced degradation.  The steady state of the system is fixed no matter what the ligand 
concentration is; consequently, changes in ligand concentration can only elicit transient 
responses that completely adapt to the prestimulus level.  The system exhibits perfect 
adaptation (Csete and Doyle, 2002). 
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Appendix I: Trafficking rates 
 
Internalization rate. It has been reported in Table 1 of reference (Di Guglielmo et al., 
2003) that after 15 min of labeling the receptors at the plasma membrane only 8, 6, 4, and 
2 % of the labeled receptors remain at the plasma membrane (the different percentage 
values correspond to different experimental conditions). The remaining labeled receptors 
have been internalized in either caveolin-1 positive or caveolin-1 negative vesicles. By 
using the formula   
1
lni tk f
t
= − , where ki  is the internalization rate and ft  the fraction 
of labeled receptors that remain at the plasma membrane after a time t , we obtain 
internalization rates of 1/5.9, 1/5.3, 1/4.7, and 1/3.8 
1min− , respectively. We have chosen 
1/(3min)ik =  for comparison with experimental data in figure 5b. 
 
Figure 4 of reference (Mitchell et al., 2004)  shows that 1.7% of the total number of 
receptors are internalized per minute. When this value is rescaled by the fraction of 
receptors in the plasma membrane, it translates into 18% of surface receptors internalized 
per minute. This implies that this internalization rate is 1/(5.3min)ik = , which is similar 
to the results obtained from reference (Di Guglielmo et al., 2003). 
 
Ligand-induced degradation rate. Active ligand-receptor complexes in lipid raft–
caveolar compartments can recruit Smad7-Smurf2 (Monteleone et al., 2004), which then 
targets them for degradation (Di Guglielmo et al., 2003). Reference (Di Guglielmo et al., 
2003) shows that receptors are internalized through the clathrin pathway and lipid raft–
caveolar compartments with similar rates. We have chosen 1/(4min)lidk =  for 
comparison with experimental data  in figure 5b.  
 
Constitutive degradation rate. Figure 3 of reference (Di Guglielmo et al., 2003) shows 
that when the lipid raft–caveolar pathway is blocked with nystatin, only ~30% of the 
initially labeled receptors remain in the cell after 8 hours. This gives a characteristic 
degradation time of ~400 min with respect to the total number of receptors. Rescaling 
this number to the plasma membrane receptors we obtain 
 
k
cd
= −
k
r
k
r
+ k
i
1
480min
ln0.3 =1/(36 min). We have chosen 
 
k
cd
= 1 / (36min)  for 
comparison with experimental data  in figure 5b.  
 
Recycling rate. Figure 3 of reference (Mitchell et al., 2004) shows that after about 30 min 
cells stop secreting internally labeled TGF-β receptors.  This recycling rate is similar to 
that for the EGF receptor. We have chosen 30minrk =  for comparison with 
experimental data  in figure 5b. 
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Appendix II: Steady and quasi-steady state analysis 
 
In this appendix we study the steady state of the system with a single ligand. By equating 
to zero the derivatives in the model equations of Figure 4, we obtain that the steady-state 
number of internalized ligand-receptor complexes is   
 
[lR
I
R
II
] =
k
i
k
r
k
a
[l][R
I
][R
II
]
(k
cd
+ k
lid
+ k
i
)
,  
where the steady-state number of type I and type II receptors at the plasma membrane are 
obtained by solving the equations  
 
0 = a
I
− c[R
I
][R
II
] − [R
I
] ,
0 = a
II
− c[R
I
][R
II
] − [R
II
] ,
 
with  
 
a
I
=
p
RI
k
cd
, a
II
=
p
RII
k
cd
,   and c =
k
cd
+ k
lid
+ (1 − α )k
i
(k
cd
+ k
lid
+ k
i
)
k
a
k
cd
[l]. 
The solution of these equations is 
 
[R
I
] =
a
I
− a
II
2
+
1+ 2(a
I
+ a
II
)c + (a
I
− a
II
)2 c2 − 1
2c
,
[R
II
] =
a
II
− a
I
2
+
1+ 2(a
II
+ a
I
)c + (a
II
− a
I
)2 c2 − 1
2c
,
 
 
which leads to 
 
[lR
I
R
II
] =
k
i
k
cd
(1+ (a
I
+ a
II
)c − 1+ 2(a
I
+ a
II
)c + (a
I
− a
II
)2 c2 )
k
r
(k
cd
+ k
lid
+ (1 − α )k
i
)2c
.  
 
For low values of c , the previous equation reduces to 
 
[lR
I
R
II
] =
k
i
k
cd
a
I
a
II
c
k
r
(k
cd
+ k
lid
+ (1 − α )k
i
)
, 
which indicates that the steady-state number of internalized ligand-receptor complexes is 
proportional to the ligand concentration and the production of each receptor type. 
 
For high values of c , in contrast, we obtain  
 
[lR
I
R
II
] =
k
i
k
cd
a
II
k
r
(k
cd
+ k
lid
+ (1− α )k
i
)
  if   a
II
≤ a
I
,   
and 
 
[lR
I
R
II
] =
k
i
k
cd
a
I
k
r
(k
cd
+ k
lid
+ (1− α )k
i
)
  if   a
I
≤ a
II
. 
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Therefore, for high ligand concentration or low constitutive degradation the steady-state 
number of internalized ligand-receptor complexes is controlled by the receptor with the 
smallest production rate and this number does not depend on the ligand concentration.  
 
The case of high c  and low constitutive degradation is specially interesting because the 
steady-state signal does not depend on the ligand concentration, even when the ligand is 
present in small quantities. An important question to address now is: can the system 
detect changes in concentration in this regime?  When the recycling rate is much lower 
than the internalization rate, the number on ligand receptor complexes in the plasma 
membrane equilibrates faster than all the other variables. Therefore assuming quasi-
equilibrium in this variable, 
 
d
dt
[lR
I
R
II
] = 0 , we obtain that, upon changes in the ligand 
concentration ( Δ[l] ), the changes in the number of ligand receptor-complexes in the 
plasma membrane (
 
Δ[lR
I
R
II
] )  follow the equation 
 
0 = k
a
([l] + Δ[l])([R
I
] − Δ[lR
I
R
II
])([R
II
] − Δ[lR
I
R
II
]) − (k
cd
+ k
lid
+ k
i
)([lR
I
R
II
] + Δ[lR
I
R
II
]).  
Note that we have assumed that the number of receptors in the plasma membrane is 
conserved at these time scales. For small changes in ligand concentration, we obtain 
 
Δ[lR
I
R
II
] =
k
a
Δ[l][R
I
][R
II
]
k
a
[l]([R
I
] + [R
II
]) + k
cd
+ k
lid
+ k
i
.  
This expression indicates that for high c , low constitutive degradation, and slow 
recycling (compared to internalization) the system can detect changes in ligand 
concentration while keeping a steady-state signal that does not depend on ligand 
concentration. 
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Appendix III: Two-compartment model of receptor trafficking for two 
ligands 
 
The equations for a system with two ligands with concentrations 1[ ]l  and 2[ ]l  are:  
 
d
dt
[l
1
R
I
R
II ,1
] = k
a
[l
1
][R
I
][R
II ,1
] − (k
cd
+ k
lid
+ k
i
)[l
1
R
I
R
II ,1
]
d
dt
[l
2
R
I
R
II ,2
] = k
a
[l
2
][R
I
][R
II ,2
] − (k
cd
+ k
lid
+ k
i
)[l
1
R
I
R
II ,2
]
d
dt
[R
I
] = p
RI
− k
a
[l
1
][R
I
][R
II ,1
] − k
a
[l
2
][R
I
][R
II ,2
] − (k
cd
+ k
i
)[R
I
] + k
r
[R
I
]
+αk
r
[l
1
R
I
R
II ,1
] + αk
r
[l
2
R
I
R
II ,2
]
d
dt
[R
II ,1
] = p
RII ,1
− k
a
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1
][R
I
][R
II ,1
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i
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II ,1
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r
[R
II ,1
]
+αk
r
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1
R
I
R
II ,1
]
d
dt
[R
II ,2
] = p
RII ,2
− k
a
[l
2
][R
I
][R
II ,2
] − (k
cd
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i
)[R
II ,2
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r
[R
II ,2
]
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r
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I
R
II ,2
]
d
dt
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I
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i
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1
R
I
R
II ,1
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r
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1
R
I
R
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]
d
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[l
2
R
I
R
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i
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1
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I
R
II ,2
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r
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2
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I
R
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d
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[R
I
] = k
i
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I
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r
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I
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d
dt
[R
II ,1
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i
[R
II ,1
] − k
r
[R
II ,1
]
d
dt
[R
II ,2
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i
[R
II ,2
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r
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II ,2
]
 
 
The variables 
 
[R
I
] , ,1[ ]IIR , and ,2[ ]IIR  are the numbers of type I and type II receptors in 
the plasma membrane; and 1 ,1[ ]I IIl R R  and 2 ,2[ ]I IIl R R  refer to the corresponding ligand-
receptor complexes. The overline indicates internalized receptors and ligand-receptor 
complexes. The signaling activity triggered by each ligand is assumed to be proportional 
to the corresponding number of internalized ligand-receptor complexes. 
 
k
a
 is the rate 
constant of ligand-receptor complex formation; 
 
p
RI
, 
 
p
RII ,1
 and 
 
p
RII ,2
 are the rates of 
receptor production; 
 
k
i
, 
 
k
r
, cdk , and  
k
lid
 are the internalization, recycling, constitutive 
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degradation, and ligand-induced degradation rate constants; and α is the fraction of 
active receptors that are recycled back to the plasma membrane and can interact again 
with the ligand. 
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Figure Legends 
 
Figure 1 
Formation of receptor hetero-tetramers 
The active form of the TGF-β ligand is a dimer of two molecules held together by 
hydrophobic interactions and a disulfide bond (Massague, 1998; Sun and Davies, 1995).  
This dimer induces the formation, at the plasma membrane, of receptor hetero-tetramers 
that contain two type I and two type II receptors (Goumans et al., 2003; Yamashita et al., 
1994).  The type II receptors phosphorylate the type I receptors; the type I receptors are 
then enabled to phosphorylate cytoplasmic R-Smads, which then act as transcriptional 
regulators. 
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Figure 2 
Interactions among the ligands of the TGF-β  superfamily and their 
receptors 
(based on data reviewed in reference (de Caestecker, 2004)) 
 
The graphical representation lays out the specific type II/type I receptor complexes that 
different ligands mediate.  Each set of links drawn between a type II and type I receptor, 
mediated by a connecting ligand, represents a feasible ligand-receptor complex.  The 14 
ligands, 5 type II and 7 type I receptors shown here give rise to 50 different combinations 
of ligand-receptor complexes overall.  Note that many of these 50 complexes share ligand 
and receptor species. 
 
The ligand-receptor complexes phosporylate the cytoplasmic R-Smads; at this point the 
signal is essentially funneled into two different pathways.  The decision which one is 
chosen depends on the particular type I receptor in the ligand-receptor complex.  The 
type I receptors can be divided into two groups, depending on which subgroup of 
R-Smads they bind and phosphorylate: The first group of type I receptors (Alk1/2/3/6, 
shown on the top right) bind and activate the R-Smads Smad1/5/8, whereas the second 
group (Alk4/5/7, shown on the bottom right) act on the R-Smads Smad2/3.  The 
phosphorylated R-Smads then form complexes with the Co-Smad Smad4. 
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Figure 3 
Signaling and trafficking in the TGF-β  pathway 
 
Receptors in the plasma membrane interact with the signaling peptides of the TGF-β 
superfamily to form active complexes.  Receptors and activated ligand-receptor 
complexes can internalize via clathrin-coated pits into endosomes, from where the active 
ligand-receptor complexes phosphorylate the cytoplasmic R-Smads (“receptor Smads”, 
either the Smad1/5/8 or the Smad2/3 group) (Shi and Massague, 2003). 
 
The phosphorylated R-Smads form complexes with the Co-Smad (Smad4) and then 
translocate into the nucleus where they act as transcriptional regulators of about 300 
target genes. 
 
The internalized receptors recycle back to the plasma membrane (with a characteristic 
time of ~30 minutes) via a rab11-dependent, rab4-independent pathway (Mitchell et al., 
2004).  After returning to the plasma membrane, the receptors that were actively 
signaling can be targeted for degradation or be used for further ligand-binding or 
internalization (Mitchell et al., 2004).  Receptors that did not bind ligands are simply 
returned to the plasma membrane.  As a consequence of the trafficking processes only 
about 5-10% of receptors are present in the plasma membrane (Di Guglielmo et al., 
2003). 
 
In addition to the traditional clathrin pathway, active ligand receptor-complexes can 
recruit Smad7-Smurf2 (Monteleone et al., 2004), which then targets them to lipid raft–
caveolar compartments (right) for degradation (Di Guglielmo et al., 2003).  
 
The ligands do not return back to the plasma membrane, but disassociate from the 
receptors before recycling and undergo direct degradation via the lysosomes (Mitchell et 
al., 2004). 
 
Note that, in addition to the ligand-induced receptor degradation, we also consider a 
receptor degradation pathway that functions independently of ligand-binding; this 
represents a “constitutive” or ligand-independent degradation pathway (left). 
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Figure 4 
Two-compartment model of receptor trafficking and signaling 
 
Graphical representation and equations for a model with one ligand that forms complexes 
with one type I and one type II receptor. Receptors are present in two main 
compartments: the plasma membrane (receptors at the cell surface) and the endosomes 
(internalized receptors).  Receptors and ligand-receptor complexes traffic between these 
two compartments by internalization and recycling.  Only internalized ligand-bound 
receptors have kinase activity.  Active receptors can also be internalized in a degradation 
pathway (right).  In addition, receptors in the plasma membrane can undergo constitutive 
degradation, independently of whether they are ligand-bound (left).  A supply of new 
receptors is constantly produced by gene expression. 
 
The concentration of the ligand is denoted by 
 
[l ] ; the numbers of type I and II receptor 
and ligand-receptor complexes in the plasma membrane, by 
 
[R
I
] , 
 
[R
II
] , and 
 
[l R
I
R
II
] , 
respectively; and the numbers of internalized type I and II receptor and ligand-receptor 
complexes by 
 
[R
I
] , 
 
[R
II
] , and 
 
[l R
I
R
II
] , respectively. (Note that type II receptors are not 
shown in the graphical representation.) The signaling activity of the pathway is assumed 
to be proportional to the number of internalized ligand-receptor complexes,  
 
[l R
I
R
II
] . 
 
k
a
 
is the rate constant of ligand-receptor complex formation;  
 
p
RI
 and 
 
p
RII
 are the rates of 
receptor production; 
 
k
i
, 
 
k
r
, cdk , and  
k
lid
 are the internalization, recycling, constitutive 
degradation, and ligand-induced degradation rate constants; α is the fraction of active 
receptors that are recycled back to the plasma membrane and can interact again with the 
ligand. 
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Figure 5 
Typical time courses of the number of active receptor complexes upon 
addition of TGF-β  
 
The typical response to sustained changes in TGF-β concentration shows partial 
adaptation after reaching a maximum of activity. Different values of the parameters of the 
model lead to this characteristic behavior. In all panels, the TGF-β concentration is 
increased at time zero to saturating values and kept constant afterwards, as in panel a) 
inset. 
 
a) Behavior of the model for typical trafficking rates: internalization, ki = (3 min)
-1
; 
recycling, kr = (30 min)
-1
; constitutive degradation, kcd = (36 min)
-1
; ligand-induced 
degradation klid= (4 min)
-1
; efficiency of recycling of active receptors, α=1. Note that the 
trafficking rate constants are given as the inverse of the corresponding characteristic 
times. The production of receptors is pRI = 8 min
-1
 and  pRII = 4 min
-1
. The units of ligand 
concentration are chosen so that the association rate constant is the unity, ka = 1. For these 
units, EC50  0.0002. At time zero the ligand concentration changes from 0.00003 to 0.01. 
The signal peaks at ~60 min.  
 
b) Comparison of the model time course (upper lane) with an experimental time course of 
nuclear, phosphorylated Smad2 (P-Smad) as reported by Inman et al. (bottom lane) 
(Inman et al., 2002). The model results from panel a are shown at the experimental time 
points and color-coded to ease comparison. 
 
c) Behavior of the model with the same parameter values as in panel a, with the exception 
of the rate constants for internalization and recycling that have been decreased to ki = 
(10 min)
-1
 and kr = (100 min)
-1
. The signal peaks at ~180 min. 
 
d) Behavior of the model with the same parameter values as in panel a, with the 
exception of the rate constants for internalization and recycling that have been increased 
to ki = (1 min)
-1
 and kr = (10 min)
-1
. The signal peaks at ~20 min. 
 
e) Behavior of the model with the same parameter values as in panel a, with the exception 
of the rate constant for ligand-induced degradation that has been decreased to klid = 0 and 
the efficiency of recycling of active receptors that has been decreased to α=0.5. This 
implies that ligand-receptor complexes are not degraded via the caveolae pathway. In 
contrast, 50% of the active ligand-receptors that come back to the plasma membrane after 
they have signaled are degraded.  
 
f) Behavior of the model with the same parameter values as in panel a, with the exception 
of the efficiency of recycling of active receptors that has been decreased to α=0.5. These 
parameters account for both types (caveola-dependent and recycling-dependent) of 
ligand-induced degradation. 
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Figure 6 
Control of the kinetic signaling behavior 
A key control quantity of the qualitative behavior of the system is the constitutive-to-
induced degradation ratio (CIR). Panels on the left (a, c, and e) show the typical behavior 
of the system for different CIR values. The TGF-β concentration is increased at time zero 
to saturating values and remains constant afterwards (panel a inset). Panels on the right 
(b, d, and f) show the behavior of the system for the same parameter values as the 
corresponding panels on the left but when TGF-β concentration is increased slowly 
(panel b inset).  
 
a,b) Same parameter values as in Figure 5a with the exception that the constitutive and 
ligand-induced degradation rates have been decreased and increased by a factor three, 
respectively: kcd = (3×36 min)
-1
; ligand-induced degradation klid= (4/3 min)
-1
. 
 
c,d) Same parameter values as in Figure 5a. Figure in panel c is exactly the same as 
Figure 5a.  
 
e,f) Same parameter values as in Figure 5a with the exception that the constitutive and 
ligand-induced degradation rates have been increased and decreased by a factor three, 
respectively: kcd = (36/3 min)
-1
; ligand-induced degradation klid= (3×4 min)
-1
. 
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Figure 7 
Control of signal integration  
Time courses of the numbers of active receptor complexes when TGF-β concentration (in 
red) is increased, repeatedly in steps or continuously.  Left panels (a, c, and e) show the 
responses to step increases as shown in panel a inset. Right panels (b, d, f) show the 
response to a continuous increase as shown in panel b inset. There is also a second ligand 
present (here BMP7, in blue) whose concentration is kept constant.  The two ligands 
induce the formation of two ligand-receptor complexes, CBMP7 (blue) and CTGF-β (red), 
that share the type I receptor Alk2. The green line on the left panels shows the total 
number of active receptor complexes (CBMP7 + CTGF-β). As in Figure 6, a key control 
quantity of the qualitative behavior of the system is the constitutive-to-induced 
degradation ratio (CIR). The parameter values for panels a, b, c, d, e, and f are the same 
as in Figures 6a, 6b, 6c, 6d, 6e, and 6f, respectively. 
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